EphA3, a novel target for leukaemia stem cell therapy

EphA3，白血病干细胞治疗的新靶点

• 批准号: nhmrc : GNT1099381
• 负责人: Dr Christopher Slape
• 金额: $ 61.7万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/epha3-novel-target-cell-therapy/1346056
• 关键词: EphA3; novel; target; leukaemia; stem

Patients with acute myeloid leukaemia often respond to therapy, but many relapse due to “leukemic stem cells” (LSC), the few cells in the original leukaemia which survive therapy. We focus on a protein (EphA3) which sits on LSCs and helps them interact with their environment. Disrupting this interaction may make these cells vulnerable to therapy. We aim to determine the function of EphA3 on LSCs and optimise the therapeutic use of an antibody against EphA3 which is currently in clinical trial.

急性髓性白血病患者通常对治疗有反应，但许多复发是由于“白血病干细胞”（LSC），即原始白血病中存活治疗的少数细胞。我们专注于一种蛋白质（EphA3），它位于LSC上，并帮助它们与环境相互作用。破坏这种相互作用可能会使这些细胞对治疗敏感。我们的目标是确定EphA3在LSC上的功能，并优化目前正在临床试验中的针对EphA3的抗体的治疗用途。